Treatment of Dupuytren's disease using collagenase from Clostridium histolyticum

• Published in: Revista española de cirugía ortopédica y traumatología Vol. 57; no. 6; pp. 398 - 402
• Main Authors: Martín-Ferrero, M Á, Simón-Pérez, C, Rodríguez-Mateos, J I, García-Medrano, B, Hernández-Ramajo, R, Brotat-García, M
• Format: Journal Article
• Language: English; Spanish
• Published: 01.11.2013
• ISSN: 1988-8856
• DOI: 10.1016/j.recot.2013.07.005

OBJECTIVEThe collagenase from Clostridium histolyticum is a new therapeutic option, and the first pharmacological one, in the treatment of Dupuytren's disease.MATERIAL AND METHODSA prospective study was conducted on 35 patients with Dupuytren's disease. The clinical and functional variables, as well as patient satisfaction and drug safety were evaluated.RESULTSThe functional and clinical results after its administration were good, with a rapid recovery, especially at the metacarpophalangeal (MCP) joint. The index finger contracture prior to MCP puncture was 64 degrees and after puncture it was 4 degrees. In the proximal interphalangeal (PIP) prior to puncture it was 83.3 degrees and after puncture it was 15 degrees; In the MCP/PIP prior to puncture it was 140 degrees, and after puncture it 25 degrees.CONCLUSIONSCollagenase from Clostridium histolyticum an alternative of treatment of Dupuytren's disease, mainly in the elderly. More research is required in order to clarify the rate of recurrence of the disease, the possible adverse reactions, and to compare the efficiency and permanence with other treatment options.